Clinical Trials

10 studies in Alzheimer's Disease Research Center
(all studies, either open or closed).

Filter this list of studies by location, status and more.

  1. Bridging Study of C11 PiB and F18 Flutemetamol Brain PET

    Rochester, Minn.

    Bridging Study of C11 PiB and F18 Flutemetamol Brain PET

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    About this study

    The intent of this research protocol is to test the equivalency of two amyloid imaging drugs (C11 Pittsburgh Compound B and F18 Flutemetamol). The investigators hypothesize that there will be no significant difference in the distribution of the agents to areas of amyloid deposition in the brain or to other normal brain structures. Recent data have shown similarity in the distribution of the drugs in subjects with AD or mild cognitive impairment (MCI). No comparison data of the two PET drugs in normal subjects has been published. It is important to understand differences in the images and biodistribution from the two drugs in normal subjects as nonspecific accumulation of the drugs in brain structures such as white matter appear to differ slightly and could affect image performance.

    The current clinical functional imaging standard for patients with indeterminate cognitive impairment is FDG PET. To allow a comparison of the PET amyloid imaging compounds with FDG PET, FDG PET scans will also be important to acquire in the subjects for comparison.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Rochester, Minn.

    Contact us for the latest status

    		View complete study & contact information
    Print study details

    Study IDs

    • Site IRB:

      • Rochester, Minnesota: 12-000118

    • NCT ID:

      NCT01607476

    • Sponsor Protocol Number:

      12-000118

  2. The Cognitive Effects of Lorazepam in Healthy Older Individuals with TOMM40 Variable-length Polymorphisms

    Scottsdale/Phoenix, Ariz.

    The Cognitive Effects of Lorazepam in Healthy Older Individuals with TOMM40 Variable-length Polymorphisms

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    About this study

    The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Scottsdale/Phoenix, Ariz.

    Open for enrollment

    		View complete study & contact information
    Print study details

    Study IDs

    • Site IRB:

      • Scottsdale/Phoenix, Arizona: 12-006469

    • NCT ID:

      NCT01780519

    • Sponsor Protocol Number:

      12-006469

  3. Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

    Rochester, Minn.

    Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

    • Study type:

      Observational What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    About this study

    The study is designed to assess the demographic, clinical and imaging associations with the presence of microbleeds in atypical Alzheimer's disease. The primary hypothesis is that cognitive and functional performance will be poorer in atypical Alzheimer's subjects with microbleeds compared to those without microbleeds.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Rochester, Minn.

    Contact us for the latest status

    		View complete study & contact information
    Print study details

    Study IDs

    • Site IRB:

      • Rochester, Minnesota: 12-007139

    • NCT ID:

      NCT01723553

    • Sponsor Protocol Number:

      12-007139

  4. Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study

    Jacksonville, Fla.

    Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    About this study

    5.4 million Americans have Alzheimer's disease (AD) costing $185 billion annually, while 15 million caregivers look after these individuals. AD is the sixth leading cause of death, but the only one in the top 10 causes that cannot be prevented.

    This study may demonstrate exercise in an amount attainable by many will be preventative in asymptomatic individuals including those with brain Abeta deposition already that are at impending risk of the disease. Sperling and colleagues(1) coined the research term AD-pathophysiological process (abbreviated AD-P) for use in studies such as the intervention in this proposal.

    Our long term goal is to assess whether exercise may be preventative of AD at older ages (=73, mean=75), when more than 40% of cognitively normal persons have A beta deposits, the hallmark of AD pathogenesis, in their brains. In a NIH RO1 grant submission the investigators proposed to conduct a partially blinded controlled preventative trial in 150 cognitively normal individuals, randomized in a 2:1 ratio to 18 months of moderate aerobic exercise versus 18 months of toning and stretching. All persons would have baseline and 18 month brain Abeta PET studies. The study was designed to determine whether an exercise intervention in persons mean age 75 would lead to decreased brain Abeta accumulation, increased hippocampal volume, improved cognition, and improved dementia-related biomarkers compared to the control group. The study would be unique in that the investigators would be able to examine if aerobic exercise slows the accumulation of brain Abeta in an older population, at which time Abeta deposition is common. If successful, this would provide an additional motivating reason to recommend exercise for most elderly persons.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Jacksonville, Fla.

    Closed for enrollment

    		View complete study & contact information
    Print study details

    Study IDs

    • Site IRB:

      • Jacksonville, Florida: 12-002817

    • NCT ID:

      NCT01834716

    • Sponsor Protocol Number:

      12-002817

  5. Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

    Jacksonville, Fla., Rochester, Minn.

    Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    • Study phase:

      III What is this?

      During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

    About this study

    The purpose of this study is to demonstrate the safety and efficacy of TRx0237 in the treatment of patients with behavioral variant frontotemporal dementia (bvFTD).

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Jacksonville, Fla.

    Open for enrollment

    		View complete study & contact information

    Rochester, Minn.

    Open for enrollment
    Print study details

    Study IDs

    • Site IRB:

      • Jacksonville, Florida: 12-008706
      • Rochester, Minnesota: 12-008706

    • NCT ID:

      NCT01626378

    • Sponsor Protocol Number:

      TRx-237-007

  6. DaTSCAN Imaging in Aging and Neurodegenerative Disease

    Rochester, Minn.

    DaTSCAN Imaging in Aging and Neurodegenerative Disease

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    About this study

    The investigators propose using DaTscan in patients with mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Rochester, Minn.

    Contact us for the latest status

    		View complete study & contact information
    Print study details

    Study IDs

    • Site IRB:

      • Rochester, Minnesota: 11-001999

    • NCT ID:

      NCT01453127

    • Sponsor Protocol Number:

      11-001999

  7. Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

    Scottsdale/Phoenix, Ariz.

    Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    • Study phase:

      III/IV What is this?

      During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

    About this study

    This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Scottsdale/Phoenix, Ariz.

    Closed for enrollment

    		View complete study & contact information
    Print study details

    Study IDs

    • Site IRB:

      • Scottsdale/Phoenix, Arizona: 12-007739

    • NCT ID:

      NCT01703702

    • Sponsor Protocol Number:

      18F-AV-45-A18

  8. Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

    Jacksonville, Fla.

    Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    • Study phase:

      III What is this?

      During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

    About this study

    To test the idea that solanezumab will slow the cognitive and functional decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Jacksonville, Fla.

    Open for enrollment

    		View complete study & contact information
    Print study details

    Study IDs

    • Site IRB:

      • Jacksonville, Florida: 13-005818

    • NCT ID:

      NCT01900665

    • Sponsor Protocol Number:

      H8A-MC-LZAX

  9. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738)

    Scottsdale/Phoenix, Ariz.

    An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738)

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    • Study phase:

      II/III What is this?

      During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

    About this study

    This study consists of two parts, Part I and Part II. The purpose of Part I of the study is to assess the efficacy and safety of MK-8931 compared with placebo administered for 78 weeks in the treatment of Alzheimer's Disease (AD). The primary study hypotheses for Part I are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score. The first approximately 400 participants entering Part I of the study are identified as the Safety Cohort. Participants who complete Part I of the study may choose to participate in Part II, which is a long term double-blind extension to assess efficacy and safety of MK-8931 administered for up to an additional 260 weeks.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Scottsdale/Phoenix, Ariz.

    Open for enrollment

    		View complete study & contact information
    Print study details

    Study IDs

    • Site IRB:

      • Scottsdale/Phoenix, Arizona: 13-000419

    • NCT ID:

      NCT01739348

    • Sponsor Protocol Number:

      P07738

  10. Behavioral Interventions to Prevent or Delay Dementia

    Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

    Behavioral Interventions to Prevent or Delay Dementia

    • Study type:

      Interventional What is this?

      Describes the nature of a clinical study. Types include:

      • Observational study — observes people and measures outcomes without affecting results.
      • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
      • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

    About this study

    This study will compare the effectiveness of different combinations of 5 types of behavioral interventions across patient-centered outcomes. It will also evaluate which outcomes (e.g. quality of life, cognition, function, mood) matter most to people at risk for dementia and their care partners. The results of this study have the potential to direct patients, families, and health care providers as to which combinations of behavioral interventions provide the greatest potential impact on which dementia prevention outcomes. Greater use of behavioral strategies that are targeted to the outcomes of most important to the patient will likely improve patient compliance and treatment adherence. This, in turn, can lessen the need for medication, health care, and long term care utilization.

    Participating Mayo Clinic locations

    Study statuses change often. Please contact us for help.

    Mayo Clinic Location Status Contact

    Scottsdale/Phoenix, Ariz.

    Open for enrollment

    		View complete study & contact information

    Jacksonville, Fla.

    Open for enrollment

    Rochester, Minn.

    Open for enrollment
    Print study details

    Study IDs

    • Site IRB:

      • Scottsdale/Phoenix, Arizona: 14-000885
      • Jacksonville, Florida: 14-000885
      • Rochester, Minnesota: 14-000885

    • NCT ID:

      NCT02265757

    • Sponsor Protocol Number:

      14-000885
  1. 1

The Mayo Clinic Alzheimer's Disease Research Center needs people to participate in research studies, including people with mild cognitive impairment, early dementia, Alzheimer's disease and Lewy body dementia. The Alzheimer's Disease Research Center also needs clinical trial participants who haven't been diagnosed with a memory disorder.

Learn more about clinical trials, the different types of clinical studies and deciding to volunteer for clinical studies.